Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGN-R13 in ALS
NCT06849609Phase 1Recruiting
- Start
- Jan 2025
- Primary completion
- May 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VGN-R13 in amyotrophic lateral sclerosis (ALS). Primary endpoint: Incidence and severity of adverse events up to 52 weeks. Started Jan 2025; status: recruiting.
02
Drugs
VGN-R13
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06849609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06849609.